IN2012DN05175A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05175A IN2012DN05175A IN5175DEN2012A IN2012DN05175A IN 2012DN05175 A IN2012DN05175 A IN 2012DN05175A IN 5175DEN2012 A IN5175DEN2012 A IN 5175DEN2012A IN 2012DN05175 A IN2012DN05175 A IN 2012DN05175A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- binding regions
- antigen
- disorders
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09178474 | 2009-12-09 | ||
| EP10170797 | 2010-07-26 | ||
| PCT/EP2010/069216 WO2011070088A1 (en) | 2009-12-09 | 2010-12-08 | Anti-c4.4a antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN05175A true IN2012DN05175A (OSRAM) | 2015-10-23 |
Family
ID=43629588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5175DEN2012 IN2012DN05175A (OSRAM) | 2009-12-09 | 2010-12-08 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20120321619A1 (OSRAM) |
| EP (2) | EP2510012B1 (OSRAM) |
| JP (3) | JP5989544B2 (OSRAM) |
| KR (1) | KR101931820B1 (OSRAM) |
| CN (1) | CN102812047B (OSRAM) |
| AR (1) | AR079340A1 (OSRAM) |
| AU (1) | AU2010329904B2 (OSRAM) |
| BR (1) | BR112012013915A8 (OSRAM) |
| CA (1) | CA2783338A1 (OSRAM) |
| CY (1) | CY1119051T1 (OSRAM) |
| DK (1) | DK2510012T3 (OSRAM) |
| ES (1) | ES2632748T3 (OSRAM) |
| HR (1) | HRP20170973T1 (OSRAM) |
| HU (1) | HUE034847T2 (OSRAM) |
| IL (1) | IL219801A (OSRAM) |
| IN (1) | IN2012DN05175A (OSRAM) |
| LT (1) | LT2510012T (OSRAM) |
| MX (1) | MX2012006593A (OSRAM) |
| NZ (1) | NZ600470A (OSRAM) |
| PL (1) | PL2510012T3 (OSRAM) |
| PT (1) | PT2510012T (OSRAM) |
| RS (1) | RS56161B1 (OSRAM) |
| RU (1) | RU2577977C2 (OSRAM) |
| SI (1) | SI2510012T1 (OSRAM) |
| TW (1) | TWI488642B (OSRAM) |
| WO (1) | WO2011070088A1 (OSRAM) |
| ZA (1) | ZA201203498B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5881604B2 (ja) * | 2010-06-15 | 2016-03-09 | 国立大学法人大阪大学 | 癌予後判定可能な抗体、および癌予後判定方法 |
| CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| JP2014117191A (ja) * | 2012-12-13 | 2014-06-30 | Fisheries Research Agency | リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途 |
| US10428159B2 (en) | 2014-09-09 | 2019-10-01 | Board Of Regents, The University Of Texas System | Blocking monoclonal antibodies to AGR2 and its receptor C4.4A |
| AU2016249839B2 (en) | 2015-04-17 | 2021-09-09 | Ventana Medical Systems, Inc. | Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a |
| RU2018123709A (ru) * | 2015-12-04 | 2020-01-09 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Новые антитела для лечения онкологических заболеваний |
| WO2017156280A1 (en) * | 2016-03-09 | 2017-09-14 | Viba Therapeutics, Inc. | Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a |
| CA3049661A1 (en) | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin (rspo) surrogate molecules |
| CN110234662A (zh) | 2017-01-26 | 2019-09-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| JP7052389B2 (ja) * | 2018-02-07 | 2022-04-12 | 株式会社三洋物産 | 遊技機 |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| WO2020018973A1 (en) * | 2018-07-20 | 2020-01-23 | Duke University | Anti-lypd3 car t-cell therapy for the treatment of cancer |
| EP3878966A4 (en) * | 2018-11-08 | 2022-10-26 | National University Corporation Kagawa University | PROCESS FOR THE PRODUCTION OF A RARE SUGAR COMPOUND AND RARE SUGAR COMPOSITION |
| CN111349164B (zh) * | 2018-12-21 | 2023-05-26 | 艾比玛特医药科技（上海）有限公司 | 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用 |
| AU2020298326A1 (en) | 2019-06-21 | 2022-01-27 | Children's National Medical Center | Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context |
| US20220395532A1 (en) | 2019-11-08 | 2022-12-15 | Humanigen, Inc. | Epha3 directed car-t cells for treatment of tumors |
| TW202233656A (zh) | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
| IL315431A (en) | 2022-03-16 | 2024-11-01 | Pentixapharm Ag | Antibodies against lypd3 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| EP0938505B1 (en) * | 1996-05-31 | 2002-03-06 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1220919A2 (en) * | 1999-09-29 | 2002-07-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Metastasis-associated antigen c4.4a |
| AU2002314495A1 (en) * | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0510883B8 (pt) * | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| US8105602B2 (en) * | 2006-12-08 | 2012-01-31 | Tactic Pharma, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
| CA2833477A1 (en) * | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
-
2010
- 2010-12-08 PT PT107989964T patent/PT2510012T/pt unknown
- 2010-12-08 AU AU2010329904A patent/AU2010329904B2/en not_active Ceased
- 2010-12-08 NZ NZ600470A patent/NZ600470A/en not_active IP Right Cessation
- 2010-12-08 JP JP2012542543A patent/JP5989544B2/ja not_active Expired - Fee Related
- 2010-12-08 IN IN5175DEN2012 patent/IN2012DN05175A/en unknown
- 2010-12-08 ES ES10798996.4T patent/ES2632748T3/es active Active
- 2010-12-08 EP EP10798996.4A patent/EP2510012B1/en active Active
- 2010-12-08 HR HRP20170973TT patent/HRP20170973T1/hr unknown
- 2010-12-08 US US13/514,789 patent/US20120321619A1/en not_active Abandoned
- 2010-12-08 LT LTEP10798996.4T patent/LT2510012T/lt unknown
- 2010-12-08 EP EP16191498.1A patent/EP3144323A3/en not_active Withdrawn
- 2010-12-08 TW TW099142735A patent/TWI488642B/zh not_active IP Right Cessation
- 2010-12-08 SI SI201031493T patent/SI2510012T1/sl unknown
- 2010-12-08 WO PCT/EP2010/069216 patent/WO2011070088A1/en not_active Ceased
- 2010-12-08 MX MX2012006593A patent/MX2012006593A/es active IP Right Grant
- 2010-12-08 CA CA2783338A patent/CA2783338A1/en not_active Abandoned
- 2010-12-08 RS RS20170650A patent/RS56161B1/sr unknown
- 2010-12-08 BR BR112012013915A patent/BR112012013915A8/pt not_active Application Discontinuation
- 2010-12-08 CN CN201080063444.XA patent/CN102812047B/zh not_active Expired - Fee Related
- 2010-12-08 RU RU2012128343/10A patent/RU2577977C2/ru not_active IP Right Cessation
- 2010-12-08 PL PL10798996T patent/PL2510012T3/pl unknown
- 2010-12-08 DK DK10798996.4T patent/DK2510012T3/en active
- 2010-12-08 KR KR1020127017608A patent/KR101931820B1/ko not_active Expired - Fee Related
- 2010-12-08 HU HUE10798996A patent/HUE034847T2/en unknown
- 2010-12-09 AR ARP100104549A patent/AR079340A1/es unknown
-
2012
- 2012-05-14 ZA ZA2012/03498A patent/ZA201203498B/en unknown
- 2012-05-15 IL IL219801A patent/IL219801A/en not_active IP Right Cessation
-
2016
- 2016-03-03 JP JP2016040961A patent/JP6240696B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-06 US US15/425,397 patent/US20170158775A1/en not_active Abandoned
- 2017-07-04 CY CY20171100712T patent/CY1119051T1/el unknown
- 2017-11-02 JP JP2017212592A patent/JP2018019721A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN05175A (OSRAM) | ||
| TN2010000234A1 (en) | Anti-mesothelin antibodies and uses therefor | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| SG142330A1 (en) | Anti-cd38 human antibodies and uses therefor | |
| MX2024015844A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| TW200716674A (en) | Anti-GM-CSF antibodies and uses therefor | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
| MX2019013172A (es) | Composiciones y metodos para tratar la enfermedad de huntington. | |
| PH12018500694A1 (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| MX373485B (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| PH12014502854A1 (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| EA202090956A2 (ru) | Антитела к cd73 и их применения | |
| UA106492C2 (uk) | Імунокон'югати анти-мезотеліну, їх застосування та одержання | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| WO2015108998A8 (en) | Cartilage targeting agents and their use | |
| PH12013500990A1 (en) | Neutralizing anti-ccl20 antibodies | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów | |
| MX2011008456A (es) | Anticuerpos anti-mst1r y usos de los mismos. | |
| CA2949045A1 (en) | Alpha-enolase specific antibodies and methods of uses in cancer therapy | |
| MX2013001836A (es) | Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc. | |
| WO2009130296A3 (en) | Anti-alk1 antibodies and uses thereof | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 |